Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

STAT5 inhibitor

DRUG CLASS:

STAT5 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

BS-HH-002.SA (0)

BS-HH-002.SA (0)

›

KMT2A rearrangement	Acute Lymphocytic Leukemia	KMT2A rearrangement	Acute Lymphocytic Leukemia	CEP-701 Sensitive: B - Late Trials CEP-701 Sensitive : B	CEP-701 Sensitive: B - Late Trials CEP-701 Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2	CEP-701 Sensitive: C2 – Inclusion Criteria CEP-701 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	EC-70124 Sensitive: D – Preclinical EC-70124 Sensitive : D	EC-70124 Sensitive: D – Preclinical EC-70124 Sensitive : D
KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	trametinib + CEP-701 Sensitive: D – Preclinical trametinib + CEP-701 Sensitive : D	trametinib + CEP-701 Sensitive: D – Preclinical trametinib + CEP-701 Sensitive : D